Literature DB >> 10799875

Monophosphoryl lipid A and QS21 increase CD8 T lymphocyte cytotoxicity to herpes simplex virus-2 infected cell proteins 4 and 27 through IFN-gamma and IL-12 production.

Z Mikloska1, M Rückholdt, I Ghadiminejad, H Dunckley, M Denis, A L Cunningham.   

Abstract

We have shown previously that IFN-gamma pretreatment of human epidermal cells (ECs) cultured in vitro partially reverses down-regulation of surface MHC class I by HSV infection, allowing recognition by CD8 CTLs, and that HSV immediate early (IE)/early (E) proteins are the predominant targets for CD8 CTLs. In this study of 25 subjects, CD8 CTLs recognized the HSV-2 IE infected cell protein 27 (ICP27) (expressed in autologous IFN-gamma-pretreated, Vaccinia virus recombinant-infected ECs) in all subjects studied, ICP4 in 89%, and ICP0 in 11%. The main hierarchy of recognition was ICP27 > ICP4. ICP27 was the dominant target in 89% of subjects but showed great individual variability in the degree of cytotoxicity. CD8 cytotoxicity specific for HSV-2 IE proteins was enhanced by 48-67% when CD8 CTLs were coincubated with the combination of monophosphoryl lipid A and QS21 adjuvants at the time of Ag presentation. These adjuvants also significantly enhanced IL-12 and IFN-gamma production from nonadherent mononuclear cells stimulated by HSV-2-infected ECs. Addition of IL-12 and IFN-gamma at the time of initial Ag presentation enhanced CD8 cytotoxicity to levels comparable with those stimulated by the adjuvants. Addition of neutralizing Abs to IL-12 or IFN-gamma inhibited CD8 T cell cytotoxicity up to 95% when a combination of the Abs were added at the time of initial Ag presentation. Therefore, the mechanism for the enhancement of CD8 T cell cytotoxicity by adjuvants in this system appears to be via increased levels of IL-12 and IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10799875     DOI: 10.4049/jimmunol.164.10.5167

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor.

Authors:  David M Koelle; Zhi Liu; Christopher L McClurkan; Randal C Cevallos; Jeffrey Vieira; Nancy A Hosken; Clement A Meseda; Devon C Snow; Anna Wald; Lawrence Corey
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-17       Impact factor: 11.205

Review 2.  Immunology in the Clinic Review Series; focus on host responses: T cell responses to herpes simplex viruses.

Authors:  K J Laing; L Dong; J Sidney; A Sette; D M Koelle
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

3.  Innate-immunity cytokines induced by very small size proteoliposomes, a Neisseria-derived immunological adjuvant.

Authors:  C Venier; M D Guthmann; L E Fernández; L Fainboim
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

4.  A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.

Authors:  Sita Awasthi; Gregory G Mahairas; Carolyn E Shaw; Meei-Li Huang; David M Koelle; Christine Posavad; Lawrence Corey; Harvey M Friedman
Journal:  J Virol       Date:  2015-06-03       Impact factor: 5.103

5.  Th-cytotoxic T-lymphocyte chimeric epitopes extended by Nepsilon-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection.

Authors:  Xiuli Zhang; Annie Issagholian; Eric A Berg; Jordan B Fishman; Anthony B Nesburn; Lbachir BenMohamed
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

6.  Th1 memory differentiates recombinant from live herpes zoster vaccines.

Authors:  Myron J Levin; Miranda E Kroehl; Michael J Johnson; Andrew Hammes; Dominik Reinhold; Nancy Lang; Adriana Weinberg
Journal:  J Clin Invest       Date:  2018-07-19       Impact factor: 14.808

7.  Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes.

Authors:  Nancy Hosken; Patrick McGowan; Amalia Meier; David M Koelle; Paul Sleath; Felecia Wagener; Mark Elliott; Ken Grabstein; Christine Posavad; Lawrence Corey
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

8.  Immunodominant epitopes in herpes simplex virus type 2 glycoprotein D are recognized by CD4 lymphocytes from both HSV-1 and HSV-2 seropositive subjects.

Authors:  Min Kim; Janette Taylor; John Sidney; Zorka Mikloska; Neil Bodsworth; Katerina Lagios; Heather Dunckley; Karen Byth-Wilson; Martine Denis; Robert Finlayson; Rajiv Khanna; Alessandro Sette; Anthony L Cunningham
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

9.  An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs.

Authors:  Mojca Skoberne; Rhonda Cardin; Alexander Lee; Ana Kazimirova; Veronica Zielinski; Danielle Garvie; Amy Lundberg; Shane Larson; Fernando J Bravo; David I Bernstein; Jessica B Flechtner; Deborah Long
Journal:  J Virol       Date:  2013-01-30       Impact factor: 5.103

Review 10.  T-cell immunity to human alphaherpesviruses.

Authors:  Werner J D Ouwendijk; Kerry J Laing; Georges M G M Verjans; David M Koelle
Journal:  Curr Opin Virol       Date:  2013-05-08       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.